Liaoning Chengda Biotechnology Co

Liaoning Chengda Biotechnology Co Current Liabilities

The Current Liabilities of Liaoning Chengda Biotechnology Co (688739.SS) as of Oct 16, 2026 is 172.96 M CNY. In the previous year, Current Liabilities was 388.16 M CNY — a change of -55.44% (lower).

Current Liabilities

172.96 MCNY

YoY

-55.44%

Last updated:

Current Liabilities of Liaoning Chengda Biotechnology Co is 2025 172.96 M CNY. Current Liabilities of Liaoning Chengda Biotechnology Co was 2024 388.16 M CNY. It decreases by -55.44% lower compared to the previous year.

The Liaoning Chengda Biotechnology Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
95.60 M CNY
Jan 1, 2019
165.96 M CNY
Jan 1, 2020
223.46 M CNY
Jan 1, 2021
241.62 M CNY
Jan 1, 2022
252.87 M CNY
Jan 1, 2023
326.94 M CNY
Jan 1, 2024
388.16 M CNY
Jan 1, 2025
172.96 M CNY
The Liaoning Chengda Biotechnology Co Current Liabilities history
YEARCurrent LiabilitiesYoY
172.96 MCNY-55.44%
388.16 MCNY+18.73%
326.94 MCNY+29.29%
252.87 MCNY+4.66%
241.62 MCNY+8.13%
223.46 MCNY+34.65%
165.96 MCNY+73.60%
95.60 MCNY+4.82%
91.20 MCNY+79.17%
50.90 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Liaoning Chengda Biotechnology Co Stock analysis

What does Liaoning Chengda Biotechnology Co do? Liaoning Chengda Biotechnology Co., Ltd. is a prominent entity in the health care sector, specifically operating within the biotechnology industry. Headquartered in Shenyang, located in the Liaoning province of China, the company has established itself as a significant player in the development and commercialization of medical solutions. As of the latest available data, the organization employs a workforce of 1,663 full-time employees, reflecting its substantial operational scale and commitment to research and development activities. The company's primary business focus revolves around the research, development, manufacturing, and sale of vaccines, addressing critical public health needs through innovative biological products. The firm's product portfolio is centered on essential immunizations, including the rabies vaccine for human use and the freeze-dried rabies vaccine for human use. Additionally, the company produces vaccines targeting Japanese encephalitis, specifically offering the inactivated Japanese encephalitis vaccine for human use and the freeze-dried encephalitis inactivated vaccine. These products are marketed under two distinct brand names: Chengda Suda and Chengda Libao, which serve to differentiate the various offerings within the company's lineup. The strategic emphasis on these specific vaccines highlights the company's dedication to combating infectious diseases that pose significant risks to human health. Liaoning Chengda Biotechnology Co., Ltd. entered the public markets through an initial public offering on October 28, 2021, marking a significant milestone in its corporate history and providing it with greater access to capital for future growth and expansion. The company's official online presence can be found at http://www.cdbio.cn, where stakeholders and interested parties can access further information regarding its operations and developments. With its strong foundation in Shenyang and a dedicated team of professionals, the company continues to contribute to the global health care landscape by delivering high-quality vaccine solutions. The combination of its extensive employee base, specialized product range, and public market listing underscores its role as a key contributor to the biotechnology sector in China and beyond. Liaoning Chengda Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Liaoning Chengda Biotechnology Co stock

Current Liabilities of Liaoning Chengda Biotechnology Co is 172.96 M CNY in 2025.

Current Liabilities of Liaoning Chengda Biotechnology Co changed from 388.16 M CNY to 172.96 M CNY, representing a -55.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Liaoning Chengda Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Liaoning Chengda Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Liaoning Chengda Biotechnology Co

All Key Metrics — Liaoning Chengda Biotechnology Co